Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans
This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects. Ticagrelor is a P2Y12 receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and...
Saved in:
| Published in | Journal of the American College of Cardiology Vol. 61; no. 7; pp. 723 - 727 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York, NY
Elsevier Inc
19.02.2013
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0735-1097 1558-3597 1558-3597 |
| DOI | 10.1016/j.jacc.2012.11.032 |
Cover
| Abstract | This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects.
Ticagrelor is a P2Y12 receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and Patient Outcomes]). Ticagrelor has been shown to inhibit cell uptake of adenosine and enhance adenosine-mediated hyperemia responses in a dog model.
In this double-blind, placebo-controlled study, 40 healthy male subjects were randomized to receive a single dose of ticagrelor (180 mg) or placebo in a crossover fashion. Coronary blood flow velocity (CBFV) was measured by using transthoracic Doppler echocardiography at rest after multiple stepwise adenosine infusions given before and after study drug, and again after the infusion of theophylline.
Ticagrelor significantly increased the area under the curve of CBFV versus the adenosine dose compared with placebo (p = 0.008). There was a significant correlation between ticagrelor plasma concentrations and increases in the area under the curve (p < 0.001). In both treatment groups, the adenosine-induced increase in CBFV was significantly attenuated by theophylline, with no significant differences between subjects receiving ticagrelor or placebo (p = 0.39). Furthermore, ticagrelor significantly enhanced the sensation of dyspnea during adenosine infusion, and the effects were diminished by theophylline.
Ticagrelor enhanced adenosine-induced CBFV and the sensation of dyspnea in these healthy male subjects via an adenosine-mediated mechanism. (Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects; NCT01226602) |
|---|---|
| AbstractList | Objectives This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects.
Background Ticagrelor is a P2Y(12) receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and Patient Outcomes]). Ticagrelor has been shown to inhibit cell uptake of adenosine and enhance adenosine-mediated hyperemia responses in a dog model.
Methods In this double-blind, placebo-controlled study, 40 healthy male subjects were randomized to receive a single dose of ticagrelor (180 mg) or placebo in a crossover fashion. Coronary blood flow velocity (CBFV) was measured by using transthoracic Doppler echocardiography at rest after multiple stepwise adenosine infusions given before and after study drug, and again after the infusion of theophylline.
Results Ticagrelor significantly increased the area under the curve of CBFV versus the adenosine dose compared with placebo (p = 0.008). There was a significant correlation between ticagrelor plasma concentrations and increases in the area under the curve (p < 0.001). In both treatment groups, the adenosine-induced increase in CBFV was significantly attenuated by theophylline, with no significant differences between subjects receiving ticagrelor or placebo (p = 0.39). Furthermore, ticagrelor significantly enhanced the sensation of dyspnea during adenosine infusion, and the effects were diminished by theophylline.
Conclusions Ticagrelor enhanced adenosine-induced CBFV and the sensation of dyspnea in these healthy male subjects via an adenosine-mediated mechanism. (Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects; NCT01226602) (J Am Coll Cardiol 2013;61:723-7) (C) 2013 by the American College of Cardiology Foundation This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects. Ticagrelor is a P2Y12 receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and Patient Outcomes]). Ticagrelor has been shown to inhibit cell uptake of adenosine and enhance adenosine-mediated hyperemia responses in a dog model. In this double-blind, placebo-controlled study, 40 healthy male subjects were randomized to receive a single dose of ticagrelor (180 mg) or placebo in a crossover fashion. Coronary blood flow velocity (CBFV) was measured by using transthoracic Doppler echocardiography at rest after multiple stepwise adenosine infusions given before and after study drug, and again after the infusion of theophylline. Ticagrelor significantly increased the area under the curve of CBFV versus the adenosine dose compared with placebo (p = 0.008). There was a significant correlation between ticagrelor plasma concentrations and increases in the area under the curve (p < 0.001). In both treatment groups, the adenosine-induced increase in CBFV was significantly attenuated by theophylline, with no significant differences between subjects receiving ticagrelor or placebo (p = 0.39). Furthermore, ticagrelor significantly enhanced the sensation of dyspnea during adenosine infusion, and the effects were diminished by theophylline. Ticagrelor enhanced adenosine-induced CBFV and the sensation of dyspnea in these healthy male subjects via an adenosine-mediated mechanism. (Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects; NCT01226602) ObjectivesThis study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects. BackgroundTicagrelor is a P2Y 12 receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and Patient Outcomes]). Ticagrelor has been shown to inhibit cell uptake of adenosine and enhance adenosine-mediated hyperemia responses in a dog model. MethodsIn this double-blind, placebo-controlled study, 40 healthy male subjects were randomized to receive a single dose of ticagrelor (180 mg) or placebo in a crossover fashion. Coronary blood flow velocity (CBFV) was measured by using transthoracic Doppler echocardiography at rest after multiple stepwise adenosine infusions given before and after study drug, and again after the infusion of theophylline. ResultsTicagrelor significantly increased the area under the curve of CBFV versus the adenosine dose compared with placebo (p = 0.008). There was a significant correlation between ticagrelor plasma concentrations and increases in the area under the curve (p < 0.001). In both treatment groups, the adenosine-induced increase in CBFV was significantly attenuated by theophylline, with no significant differences between subjects receiving ticagrelor or placebo (p = 0.39). Furthermore, ticagrelor significantly enhanced the sensation of dyspnea during adenosine infusion, and the effects were diminished by theophylline. ConclusionsTicagrelor enhanced adenosine-induced CBFV and the sensation of dyspnea in these healthy male subjects via an adenosine-mediated mechanism. (Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects; NCT01226602) This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects. Ticagrelor is a P2Y(12) receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and Patient Outcomes]). Ticagrelor has been shown to inhibit cell uptake of adenosine and enhance adenosine-mediated hyperemia responses in a dog model. In this double-blind, placebo-controlled study, 40 healthy male subjects were randomized to receive a single dose of ticagrelor (180 mg) or placebo in a crossover fashion. Coronary blood flow velocity (CBFV) was measured by using transthoracic Doppler echocardiography at rest after multiple stepwise adenosine infusions given before and after study drug, and again after the infusion of theophylline. Ticagrelor significantly increased the area under the curve of CBFV versus the adenosine dose compared with placebo (p = 0.008). There was a significant correlation between ticagrelor plasma concentrations and increases in the area under the curve (p < 0.001). In both treatment groups, the adenosine-induced increase in CBFV was significantly attenuated by theophylline, with no significant differences between subjects receiving ticagrelor or placebo (p = 0.39). Furthermore, ticagrelor significantly enhanced the sensation of dyspnea during adenosine infusion, and the effects were diminished by theophylline. Ticagrelor enhanced adenosine-induced CBFV and the sensation of dyspnea in these healthy male subjects via an adenosine-mediated mechanism. (Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects; NCT01226602). This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects.OBJECTIVESThis study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects.Ticagrelor is a P2Y(12) receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and Patient Outcomes]). Ticagrelor has been shown to inhibit cell uptake of adenosine and enhance adenosine-mediated hyperemia responses in a dog model.BACKGROUNDTicagrelor is a P2Y(12) receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and Patient Outcomes]). Ticagrelor has been shown to inhibit cell uptake of adenosine and enhance adenosine-mediated hyperemia responses in a dog model.In this double-blind, placebo-controlled study, 40 healthy male subjects were randomized to receive a single dose of ticagrelor (180 mg) or placebo in a crossover fashion. Coronary blood flow velocity (CBFV) was measured by using transthoracic Doppler echocardiography at rest after multiple stepwise adenosine infusions given before and after study drug, and again after the infusion of theophylline.METHODSIn this double-blind, placebo-controlled study, 40 healthy male subjects were randomized to receive a single dose of ticagrelor (180 mg) or placebo in a crossover fashion. Coronary blood flow velocity (CBFV) was measured by using transthoracic Doppler echocardiography at rest after multiple stepwise adenosine infusions given before and after study drug, and again after the infusion of theophylline.Ticagrelor significantly increased the area under the curve of CBFV versus the adenosine dose compared with placebo (p = 0.008). There was a significant correlation between ticagrelor plasma concentrations and increases in the area under the curve (p < 0.001). In both treatment groups, the adenosine-induced increase in CBFV was significantly attenuated by theophylline, with no significant differences between subjects receiving ticagrelor or placebo (p = 0.39). Furthermore, ticagrelor significantly enhanced the sensation of dyspnea during adenosine infusion, and the effects were diminished by theophylline.RESULTSTicagrelor significantly increased the area under the curve of CBFV versus the adenosine dose compared with placebo (p = 0.008). There was a significant correlation between ticagrelor plasma concentrations and increases in the area under the curve (p < 0.001). In both treatment groups, the adenosine-induced increase in CBFV was significantly attenuated by theophylline, with no significant differences between subjects receiving ticagrelor or placebo (p = 0.39). Furthermore, ticagrelor significantly enhanced the sensation of dyspnea during adenosine infusion, and the effects were diminished by theophylline.Ticagrelor enhanced adenosine-induced CBFV and the sensation of dyspnea in these healthy male subjects via an adenosine-mediated mechanism. (Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects; NCT01226602).CONCLUSIONSTicagrelor enhanced adenosine-induced CBFV and the sensation of dyspnea in these healthy male subjects via an adenosine-mediated mechanism. (Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects; NCT01226602). Objectives This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects. Background Ticagrelor is a P2Y12receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and Patient Outcomes]). Ticagrelor has been shown to inhibit cell uptake of adenosine and enhance adenosine-mediated hyperemia responses in a dog model. Methods In this double-blind, placebo-controlled study, 40 healthy male subjects were randomized to receive a single dose of ticagrelor (180 mg) or placebo in a crossover fashion. Coronary blood flow velocity (CBFV) was measured by using transthoracic Doppler echocardiography at rest after multiple stepwise adenosine infusions given before and after study drug, and again after the infusion of theophylline. Results Ticagrelor significantly increased the area under the curve of CBFV versus the adenosine dose compared with placebo (p = 0.008). There was a significant correlation between ticagrelor plasma concentrations and increases in the area under the curve (p < 0.001). In both treatment groups, the adenosine-induced increase in CBFV was significantly attenuated by theophylline, with no significant differences between subjects receiving ticagrelor or placebo (p = 0.39). Furthermore, ticagrelor significantly enhanced the sensation of dyspnea during adenosine infusion, and the effects were diminished by theophylline. Conclusions Ticagrelor enhanced adenosine-induced CBFV and the sensation of dyspnea in these healthy male subjects via an adenosine-mediated mechanism. (Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects;NCT01226602) |
| Author | Brandrup-Wognsen, Gunnar Nylander, Sven Gan, Li-Ming Emanuelsson, Håkan Wittfeldt, Ann Jonasson, Jenny van Giezen, J.J.J. |
| Author_xml | – sequence: 1 givenname: Ann surname: Wittfeldt fullname: Wittfeldt, Ann organization: Department of Clinical and Molecular Medicine, Institution of Medicine, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden – sequence: 2 givenname: Håkan surname: Emanuelsson fullname: Emanuelsson, Håkan organization: AstraZeneca R&D, Mölndal, Sweden – sequence: 3 givenname: Gunnar surname: Brandrup-Wognsen fullname: Brandrup-Wognsen, Gunnar organization: Department of Clinical and Molecular Medicine, Institution of Medicine, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden – sequence: 4 givenname: J.J.J. surname: van Giezen fullname: van Giezen, J.J.J. organization: AstraZeneca R&D, Mölndal, Sweden – sequence: 5 givenname: Jenny surname: Jonasson fullname: Jonasson, Jenny organization: AstraZeneca R&D, Mölndal, Sweden – sequence: 6 givenname: Sven surname: Nylander fullname: Nylander, Sven organization: AstraZeneca R&D, Mölndal, Sweden – sequence: 7 givenname: Li-Ming surname: Gan fullname: Gan, Li-Ming email: li-ming.gan@astrazeneca.com organization: Department of Clinical and Molecular Medicine, Institution of Medicine, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27140734$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23312702$$D View this record in MEDLINE/PubMed https://gup.ub.gu.se/publication/174518$$DView record from Swedish Publication Index |
| BookMark | eNqFklFrFDEQxxep2Gv1C_ggByL4smcm2WyyIkI5qi0UClp9Dblk9sy5l2yTXaXf3ix3tnBgfVqy_P6TyfzmpDjywWNRvASyAAL1u81io41ZUAJ0AbAgjD4pZsC5LBlvxFExI4LxEkgjjouTlDaEkFpC86w4powBFYTOiusbZ_Q6Yhfi_Nz_0N5gmp9Z9CE5j-Wlt6NBO1-GGLyOd_PvOgXrOj2EfPiCqQ8-5YTz84txq316XjxtdZfwxf57Wnz7dH6zvCivrj9fLs-uSpP7G0rLZWOqWgpq0SA3hmkNrZUUYWUZN5I2DdbAGW-1aa0mArkVbSs4k4ZVK3ZalLu66Tf240r10W1zfypop9Zjr_Kv9agSKhAVB5n5tzu-j-F2xDSorUsGu057DGNSQKVkQEhTZ_T1AboJY_T5NQrqXEw0VcUz9WpPjast2vsG_o42A2_2gE5Gd23Ms3XpgRNQZT9V5uiOMzGkFLG9R4CoybPaqMmzmjwrAJU955A8CBk36MEFP0TtusejH3ZRzHp-OYwqGYfZu3URzaBscI_HPx7ETed8XqLuJ95hehiVSlQR9XXawWkFgRKenzuZeP_vAv-7_Q-Q3uqy |
| CODEN | JACCDI |
| CitedBy_id | crossref_primary_10_1002_wmts_97 crossref_primary_10_1016_j_vph_2018_11_005 crossref_primary_10_3389_fcvm_2021_820604 crossref_primary_10_1016_j_jacc_2013_04_078 crossref_primary_10_1160_TH16_04_0273 crossref_primary_10_1517_17425255_2015_1037279 crossref_primary_10_1038_jcbfm_2014_45 crossref_primary_10_1016_j_cct_2019_105835 crossref_primary_10_1007_s12265_017_9783_8 crossref_primary_10_1016_j_ahj_2019_04_006 crossref_primary_10_1016_j_jcin_2015_03_010 crossref_primary_10_1161_CIRCULATIONAHA_118_035931 crossref_primary_10_1007_s12265_013_9527_3 crossref_primary_10_1160_TH13_11_0915 crossref_primary_10_1161_JAHA_119_015785 crossref_primary_10_1007_s00228_018_2427_3 crossref_primary_10_1161_ATVBAHA_114_303412 crossref_primary_10_3390_jcm13175235 crossref_primary_10_1016_j_jcin_2013_03_014 crossref_primary_10_1016_j_jacc_2022_08_797 crossref_primary_10_1002_jppr_1119 crossref_primary_10_1007_s11906_023_01272_2 crossref_primary_10_1253_circj_CJ_17_0632 crossref_primary_10_1007_s12265_013_9497_5 crossref_primary_10_1186_s12947_016_0091_2 crossref_primary_10_1016_j_ijcard_2016_04_179 crossref_primary_10_1016_j_jacc_2013_05_039 crossref_primary_10_1517_14656566_2015_1005602 crossref_primary_10_1002_prp2_338 crossref_primary_10_1080_09537104_2016_1265919 crossref_primary_10_1016_j_biopha_2023_115184 crossref_primary_10_1161_CIRCULATIONAHA_118_034790 crossref_primary_10_1016_j_thromres_2021_01_026 crossref_primary_10_3390_ijms242417546 crossref_primary_10_3390_app121910021 crossref_primary_10_3109_09537104_2015_1049519 crossref_primary_10_1016_j_ahj_2015_06_014 crossref_primary_10_1177_1074248419841640 crossref_primary_10_1016_j_mednuc_2019_09_002 crossref_primary_10_1042_CS20201445 crossref_primary_10_1007_s00059_015_4359_3 crossref_primary_10_1080_09537104_2018_1478404 crossref_primary_10_1160_TH14_12_1068 crossref_primary_10_1097_HPC_0000000000000322 crossref_primary_10_1177_1179547620956634 crossref_primary_10_2174_0113816128309440240427102903 crossref_primary_10_1016_j_ijcard_2015_08_067 crossref_primary_10_1016_j_jacc_2013_12_053 crossref_primary_10_1253_circj_CJ_15_0112 crossref_primary_10_1152_ajpheart_00570_2020 crossref_primary_10_1016_j_ahj_2018_02_011 crossref_primary_10_1177_1074248413511693 crossref_primary_10_3390_ma13132913 crossref_primary_10_1016_j_ijcard_2015_08_162 crossref_primary_10_4244_EIJV12I8A159 crossref_primary_10_1007_s12265_020_10062_z crossref_primary_10_1007_s40256_015_0108_5 crossref_primary_10_3904_kjim_2019_293 crossref_primary_10_1002_phar_1477 crossref_primary_10_3390_ijms21051576 crossref_primary_10_1016_j_ijcard_2015_03_414 crossref_primary_10_1186_s12872_021_02030_5 crossref_primary_10_1096_fj_201600616R crossref_primary_10_1056_NEJMoa1908973 crossref_primary_10_1093_eurheartj_suu030 crossref_primary_10_1002_pds_3884 crossref_primary_10_1016_j_hlc_2023_03_010 crossref_primary_10_3390_biom10050740 crossref_primary_10_1016_j_echo_2021_07_012 crossref_primary_10_1007_s43440_021_00309_0 crossref_primary_10_1111_bph_13429 crossref_primary_10_1016_j_carrev_2021_06_129 crossref_primary_10_1016_j_cjca_2018_08_024 crossref_primary_10_1021_acs_jmedchem_8b01818 crossref_primary_10_1161_CIRCINTERVENTIONS_121_011419 crossref_primary_10_4103_0366_6999_244106 crossref_primary_10_1186_s12933_019_0882_5 crossref_primary_10_1097_MCA_0000000000000761 crossref_primary_10_36660_abc_20201076 crossref_primary_10_1186_s12933_017_0543_5 crossref_primary_10_1007_s10557_017_6749_7 crossref_primary_10_1016_j_cpcardiol_2023_102019 crossref_primary_10_1038_s41598_017_12205_w crossref_primary_10_31083_j_rcm2202044 crossref_primary_10_3109_09537104_2013_842965 crossref_primary_10_1016_j_vph_2015_02_006 crossref_primary_10_1177_2040622315584113 crossref_primary_10_1371_journal_pone_0176511 crossref_primary_10_1016_S1131_3587_14_70098_6 crossref_primary_10_1177_1074248418786936 crossref_primary_10_1080_17474086_2020_1817736 crossref_primary_10_1124_pr_113_008029 crossref_primary_10_1093_ehjcvp_pvad092 crossref_primary_10_1186_s13063_020_4116_7 crossref_primary_10_1016_j_ahj_2018_07_013 crossref_primary_10_1016_j_amjcard_2015_09_044 crossref_primary_10_1016_j_jcin_2017_05_064 crossref_primary_10_1007_s11302_014_9436_1 crossref_primary_10_2147_DDDT_S435477 crossref_primary_10_1016_j_jacc_2016_02_023 crossref_primary_10_1161_JAHA_119_014411 crossref_primary_10_23736_S0026_4806_19_05859_2 crossref_primary_10_1186_s12959_023_00559_3 crossref_primary_10_1111_jth_12360 crossref_primary_10_1161_JAHA_117_005894 crossref_primary_10_1177_0897190016680978 crossref_primary_10_1586_14779072_2013_839205 crossref_primary_10_1111_bcpt_12752 crossref_primary_10_1002_ejhf_2709 crossref_primary_10_1016_j_cardfail_2021_02_005 crossref_primary_10_1185_03007995_2015_1058247 crossref_primary_10_1016_j_jacc_2014_02_539 crossref_primary_10_1007_s40265_017_0844_8 crossref_primary_10_2174_1570161116666180206110657 crossref_primary_10_1002_ccd_27196 crossref_primary_10_1161_JAHA_119_012521 crossref_primary_10_1007_s40256_014_0071_6 crossref_primary_10_1097_MCA_0000000000000707 crossref_primary_10_1016_j_hjc_2017_12_008 crossref_primary_10_1177_1074248420968693 crossref_primary_10_1007_s40265_013_0126_z crossref_primary_10_1111_bph_16146 crossref_primary_10_1007_s00395_021_00859_7 crossref_primary_10_1016_j_hrcr_2018_07_017 crossref_primary_10_1016_j_jcin_2013_04_006 crossref_primary_10_4070_kcj_2017_0044 crossref_primary_10_1007_s40262_021_01089_9 crossref_primary_10_1093_eurheartj_sux013 crossref_primary_10_1111_1440_1681_12097 crossref_primary_10_15829_1560_4071_2022_5021 crossref_primary_10_3390_ijms241310844 crossref_primary_10_1093_eurheartj_ehy531 crossref_primary_10_1016_j_ijcard_2017_04_108 crossref_primary_10_1021_acsmedchemlett_0c00441 crossref_primary_10_1371_journal_pone_0137560 crossref_primary_10_1016_j_ahj_2018_04_020 crossref_primary_10_26559_mersinsbd_1018841 crossref_primary_10_1007_s40262_015_0290_2 crossref_primary_10_1007_s00392_016_1043_4 crossref_primary_10_1007_s00395_021_00870_y crossref_primary_10_1016_j_jacc_2017_02_048 crossref_primary_10_1016_j_iccl_2016_08_004 crossref_primary_10_1016_j_jcin_2015_11_026 crossref_primary_10_1016_j_conctc_2020_100629 crossref_primary_10_1136_heartjnl_2023_323034 crossref_primary_10_15212_CVIA_2017_0049 crossref_primary_10_2174_1871529X18666181011103719 crossref_primary_10_1161_CIRCINTERVENTIONS_113_000293 crossref_primary_10_4103_2468_5658_196982 crossref_primary_10_1016_j_jacc_2013_09_067 crossref_primary_10_2459_JCM_0000000000001345 crossref_primary_10_1371_journal_pone_0205707 crossref_primary_10_1007_s11302_018_9616_5 crossref_primary_10_1016_j_jacc_2013_09_068 crossref_primary_10_1155_2018_8572740 crossref_primary_10_1080_14779072_2016_1247693 crossref_primary_10_1111_cpf_12523 crossref_primary_10_1016_j_cjca_2019_04_026 crossref_primary_10_1016_j_jacc_2014_03_031 crossref_primary_10_4037_ccn2016497 crossref_primary_10_1016_j_carrev_2014_07_001 crossref_primary_10_1080_17425255_2016_1244524 crossref_primary_10_1097_MCA_0000000000001265 crossref_primary_10_1016_j_phrs_2017_12_035 crossref_primary_10_1161_JAHA_116_004875 |
| Cites_doi | 10.1161/01.CIR.83.5.1499 10.1161/atvb.32.suppl_1.A213 10.1016/j.jacc.2005.02.061 10.1111/j.1538-7836.2009.03527.x 10.1016/S0735-1097(99)00418-0 10.1016/j.jchromb.2010.06.018 10.1152/ajpheart.00135.2005 10.1038/sj.cdd.4402132 10.1177/1074248411410883 10.1016/j.jacc.2010.11.056 10.1056/NEJMoa0904327 10.1152/japplphysiol.00913.2004 |
| ContentType | Journal Article |
| Copyright | 2013 American College of Cardiology Foundation American College of Cardiology Foundation 2014 INIST-CNRS Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. Copyright Elsevier Limited Feb 19, 2013 |
| Copyright_xml | – notice: 2013 American College of Cardiology Foundation – notice: American College of Cardiology Foundation – notice: 2014 INIST-CNRS – notice: Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. – notice: Copyright Elsevier Limited Feb 19, 2013 |
| DBID | 6I. AAFTH AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7TK H94 K9. NAPCQ 7X8 ADTPV AOWAS F1U |
| DOI | 10.1016/j.jacc.2012.11.032 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Neurosciences Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic SwePub SwePub Articles SWEPUB Göteborgs universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Immunology Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1558-3597 |
| EndPage | 727 |
| ExternalDocumentID | oai_gup_ub_gu_se_174518 3556862441 23312702 27140734 10_1016_j_jacc_2012_11_032 S0735109712057348 1_s2_0_S0735109712057348 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Sweden |
| GeographicLocations_xml | – name: Sweden |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 18M 1B1 1P~ 1~. 1~5 2WC 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ AABNK AABVL AAEDT AAEDW AAIKJ AAOAW AAQFI AAXUO ABBQC ABFNM ABFRF ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACGFO ACGFS ACIUM ACJTP ACPRK ACVFH ADBBV ADCNI ADEZE ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFPUW AFRAH AFRHN AFTJW AGCQF AGHFR AGYEJ AHMBA AIGII AITUG AJRQY AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BLXMC CS3 DIK DU5 E3Z EBS EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FNPLU G-Q GBLVA GX1 H13 HVGLF IHE IXB J1W K-O KQ8 L7B MO0 N9A O-L O9- OA. OAUVE OK1 OL~ OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 ROL RPZ SCC SDF SDG SDP SES SSZ TR2 UNMZH UV1 W8F WH7 WOQ WOW YYM YZZ Z5R .55 .GJ 0SF 1CY 29L 3O- 3V. 6I. 7RV AACTN AAFTH AAKUH AALRI AAQQT AAQXK AAYOK ABVKL ACRPL ADMUD ADNMO AFCTW AFETI AFFNX AJOXV AMFUW ASPBG AVWKF AZFZN BENPR BPHCQ FGOYB HX~ HZ~ J5H N4W NCXOZ QTD R2- RIG SEW T5K X7M XPP YYP ZGI ZXP AAIAV ABJNI EFLBG LCYCR NAHTW ZA5 AAYWO AAYXX AGQPQ CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7TK H94 K9. NAPCQ 7X8 ADTPV AOWAS F1U |
| ID | FETCH-LOGICAL-c558t-d589c46872dece5cc3aa1fd82e1bd35c8299e61535facfda07e5d7ff7538c34b3 |
| IEDL.DBID | IXB |
| ISSN | 0735-1097 1558-3597 |
| IngestDate | Tue Sep 09 23:25:10 EDT 2025 Thu Sep 04 21:31:48 EDT 2025 Fri Jul 25 20:05:27 EDT 2025 Mon Jul 21 06:05:52 EDT 2025 Wed Apr 02 07:24:32 EDT 2025 Tue Jul 01 01:31:38 EDT 2025 Thu Apr 24 23:06:00 EDT 2025 Fri Feb 23 02:28:24 EST 2024 Sun Feb 23 10:19:02 EST 2025 Tue Aug 26 19:55:11 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | adenosine CBFV CV CI dyspnea ticagrelor coronary blood flow LAD AUC left anterior descending coronary artery area under the curve confidence interval coronary blood flow velocity coefficient of variation Human Purine nucleoside Adenosine Coronary artery Cardiovascular disease Coronary heart disease Antiplatelet agent Vasodilation Response Vasomotricity Circulatory system Cardiology Ticagrelor |
| Language | English |
| License | http://www.elsevier.com/open-access/userlicense/1.0 https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c558t-d589c46872dece5cc3aa1fd82e1bd35c8299e61535facfda07e5d7ff7538c34b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0735109712057348 |
| PMID | 23312702 |
| PQID | 1645179445 |
| PQPubID | 2031078 |
| PageCount | 5 |
| ParticipantIDs | swepub_primary_oai_gup_ub_gu_se_174518 proquest_miscellaneous_1288310096 proquest_journals_1645179445 pubmed_primary_23312702 pascalfrancis_primary_27140734 crossref_primary_10_1016_j_jacc_2012_11_032 crossref_citationtrail_10_1016_j_jacc_2012_11_032 elsevier_sciencedirect_doi_10_1016_j_jacc_2012_11_032 elsevier_clinicalkeyesjournals_1_s2_0_S0735109712057348 elsevier_clinicalkey_doi_10_1016_j_jacc_2012_11_032 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-02-19 |
| PublicationDateYYYYMMDD | 2013-02-19 |
| PublicationDate_xml | – month: 02 year: 2013 text: 2013-02-19 day: 19 |
| PublicationDecade | 2010 |
| PublicationPlace | New York, NY |
| PublicationPlace_xml | – name: New York, NY – name: United States – name: New York |
| PublicationTitle | Journal of the American College of Cardiology |
| PublicationTitleAlternate | J Am Coll Cardiol |
| PublicationYear | 2013 |
| Publisher | Elsevier Inc Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier – name: Elsevier Limited |
| References | van Giezen, Tomlinson, Berntsson (bib1) 2009; 7 Hägg, Wandt, Bergström, Volkmann, Gan (bib6) 2005; 289 Scirica, Cannon, Emanuelsson (bib12) 2011; 57 Lerman, Belardinelli (bib5) 1991; 83 Sillén, Cook, Davis (bib7) 2010; 878 Mahaffey, Puma, Barbagelata (bib10) 1999; 34 Ross, Gibbons, Stone, Kloner, Alexander (bib11) 2005; 45 Wallentin, Becker, Budaj (bib2) 2009; 361 Fredholm (bib8) 2007; 14 van Giezen, Sidaway, Glaves, Kirk, Björkman (bib3) 2011; 17 Burki, Dale, Lee (bib4) 2005; 98 Nylander, Femia, Scavone (bib9) 2012; 32 van Giezen (10.1016/j.jacc.2012.11.032_bib1) 2009; 7 Lerman (10.1016/j.jacc.2012.11.032_bib5) 1991; 83 Wallentin (10.1016/j.jacc.2012.11.032_bib2) 2009; 361 Sillén (10.1016/j.jacc.2012.11.032_bib7) 2010; 878 Fredholm (10.1016/j.jacc.2012.11.032_bib8) 2007; 14 van Giezen (10.1016/j.jacc.2012.11.032_bib3) 2011; 17 Nylander (10.1016/j.jacc.2012.11.032_bib9) 2012; 32 Scirica (10.1016/j.jacc.2012.11.032_bib12) 2011; 57 Burki (10.1016/j.jacc.2012.11.032_bib4) 2005; 98 Ross (10.1016/j.jacc.2012.11.032_bib11) 2005; 45 Mahaffey (10.1016/j.jacc.2012.11.032_bib10) 1999; 34 Hägg (10.1016/j.jacc.2012.11.032_bib6) 2005; 289 23747784 - J Am Coll Cardiol. 2013 Aug 13;62(7):647 23747764 - J Am Coll Cardiol. 2013 Aug 13;62(7):646-7 |
| References_xml | – volume: 14 start-page: 1315 year: 2007 end-page: 1323 ident: bib8 article-title: Adenosine, an endogenous distress signal, modulates tissue damage and repair publication-title: Cell Death Differ – volume: 34 start-page: 1711 year: 1999 end-page: 1720 ident: bib10 article-title: Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of Adenosine (AMISTAD) trial publication-title: J Am Coll Cardiol – volume: 878 start-page: 2299 year: 2010 end-page: 2306 ident: bib7 article-title: Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry publication-title: J Chromatogr B Analyt Technol Biomed Life Sci – volume: 45 start-page: 1775 year: 2005 end-page: 1780 ident: bib11 article-title: A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II) publication-title: J Am Coll Cardiol – volume: 361 start-page: 1045 year: 2009 end-page: 1057 ident: bib2 article-title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes publication-title: N Engl J Med – volume: 7 start-page: 1556 year: 2009 end-page: 1565 ident: bib1 article-title: AZD6140 (ticagrelor) binds to the human P2Y12 receptor independently from ADP, but antagonizes ADP-induced receptor signaling and platelet aggregation publication-title: J Thromb Haemost – volume: 98 start-page: 180 year: 2005 end-page: 185 ident: bib4 article-title: Intravenous adenosine and dyspnea in humans publication-title: J Appl Physiol – volume: 57 start-page: 1908 year: 2011 end-page: 1916 ident: bib12 article-title: The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy publication-title: J Am Coll Cardiol – volume: 32 start-page: A213 year: 2012 ident: bib9 article-title: Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism publication-title: Arterioscler Thromb Vasc Biol – volume: 289 start-page: H1627 year: 2005 end-page: H1634 ident: bib6 article-title: Physical exercise capacity is associated with coronary and peripheral vascular function in healthy young adults publication-title: Am J Physiol Heart Circ Physiol – volume: 17 start-page: 164 year: 2011 end-page: 172 ident: bib3 article-title: Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model publication-title: J Cardiovasc Pharmacol Ther – volume: 83 start-page: 1499 year: 1991 end-page: 1509 ident: bib5 article-title: Cardiac electrophysiology of adenosine publication-title: Circulation – volume: 83 start-page: 1499 year: 1991 ident: 10.1016/j.jacc.2012.11.032_bib5 article-title: Cardiac electrophysiology of adenosine publication-title: Circulation doi: 10.1161/01.CIR.83.5.1499 – volume: 32 start-page: A213 year: 2012 ident: 10.1016/j.jacc.2012.11.032_bib9 article-title: Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/atvb.32.suppl_1.A213 – volume: 45 start-page: 1775 year: 2005 ident: 10.1016/j.jacc.2012.11.032_bib11 article-title: A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II) publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2005.02.061 – volume: 7 start-page: 1556 year: 2009 ident: 10.1016/j.jacc.2012.11.032_bib1 article-title: AZD6140 (ticagrelor) binds to the human P2Y12 receptor independently from ADP, but antagonizes ADP-induced receptor signaling and platelet aggregation publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2009.03527.x – volume: 34 start-page: 1711 year: 1999 ident: 10.1016/j.jacc.2012.11.032_bib10 article-title: Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of Adenosine (AMISTAD) trial publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(99)00418-0 – volume: 878 start-page: 2299 year: 2010 ident: 10.1016/j.jacc.2012.11.032_bib7 article-title: Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry publication-title: J Chromatogr B Analyt Technol Biomed Life Sci doi: 10.1016/j.jchromb.2010.06.018 – volume: 289 start-page: H1627 year: 2005 ident: 10.1016/j.jacc.2012.11.032_bib6 article-title: Physical exercise capacity is associated with coronary and peripheral vascular function in healthy young adults publication-title: Am J Physiol Heart Circ Physiol doi: 10.1152/ajpheart.00135.2005 – volume: 14 start-page: 1315 year: 2007 ident: 10.1016/j.jacc.2012.11.032_bib8 article-title: Adenosine, an endogenous distress signal, modulates tissue damage and repair publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4402132 – volume: 17 start-page: 164 year: 2011 ident: 10.1016/j.jacc.2012.11.032_bib3 article-title: Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model publication-title: J Cardiovasc Pharmacol Ther doi: 10.1177/1074248411410883 – volume: 57 start-page: 1908 year: 2011 ident: 10.1016/j.jacc.2012.11.032_bib12 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2010.11.056 – volume: 361 start-page: 1045 year: 2009 ident: 10.1016/j.jacc.2012.11.032_bib2 article-title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes publication-title: N Engl J Med doi: 10.1056/NEJMoa0904327 – volume: 98 start-page: 180 year: 2005 ident: 10.1016/j.jacc.2012.11.032_bib4 article-title: Intravenous adenosine and dyspnea in humans publication-title: J Appl Physiol doi: 10.1152/japplphysiol.00913.2004 – reference: 23747764 - J Am Coll Cardiol. 2013 Aug 13;62(7):646-7 – reference: 23747784 - J Am Coll Cardiol. 2013 Aug 13;62(7):647 |
| SSID | ssj0006819 |
| Score | 2.5124612 |
| Snippet | This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects.
Ticagrelor... ObjectivesThis study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects.... Objectives This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects.... This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human... |
| SourceID | swepub proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 723 |
| SubjectTerms | Acute coronary syndromes acute myocardial-infarction adenosine Adenosine - analogs & derivatives Adenosine - pharmacology adjunct Adolescent Adult Biological and medical sciences Blood Flow Velocity - drug effects Blood Flow Velocity - physiology Cardiology Cardiology and Cardiovascular Disease Cardiology. Vascular system Cardiovascular clopidogrel Confidence intervals coronary blood flow Coronary heart disease Coronary Vessels - drug effects Coronary Vessels - physiology Cross-Over Studies Double-Blind Method Drug Synergism Drug therapy dyspnea Flow velocity Heart Heart attacks Humans Kardiologi och kardiovaskulära sjukdomar Male Medical sciences multicenter Physiology Purinergic P2Y Receptor Antagonists - pharmacology ticagrelor trial Up-Regulation - drug effects Up-Regulation - physiology Variance analysis Vasodilation - drug effects Vasodilation - physiology Young Adult |
| Title | Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0735109712057348 https://www.clinicalkey.es/playcontent/1-s2.0-S0735109712057348 https://dx.doi.org/10.1016/j.jacc.2012.11.032 https://www.ncbi.nlm.nih.gov/pubmed/23312702 https://www.proquest.com/docview/1645179445 https://www.proquest.com/docview/1288310096 https://gup.ub.gu.se/publication/174518 |
| Volume | 61 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9QwDLfGHhASQnxTGKciIV5Qds1XL_c4TpsmpIEEG7q3KE2TcdPUO13vHnjhb8fu1zQYQ-K1idvGdey4tn8GeDv1IctcHpgOWjFV6MgcGjamXQiiiGihM6p3PvmUH5-pj3M934FZXwtDaZWd7m91eqOtuyvjjpvj1WIx_orCqSl-ygWB-ikq-KWqUirim38YtHFumuYeNJnR7K5wps3xunCeYAy52CckTyn-Zpzur1yNLIttr4ubDqO_IY021unoITzojpXpQfvmj2AnVI_h7kkXOH8Cn08p42Id0DtPD6vv9Knr9KAkpHAcZ9TAA1mRzgjPwK1_pN9cvSwXl00IPv3S5tEixaJKm7_-9VM4Ozo8nR2zrpcC81qbDSu1mXqVm4kogw_ae-kcj6URgRel1N6gWQp0-NPR-Vi6bBJ0OYkRvRnjpSrkM9itllV4AanweSGFjzGjEGFRmKlzTkkV8yhKtPgJ8J6J1ndA49Tv4tL2GWUXlhhvifHogVhkfALvB5pVC7Nx62zZfxvbF5CiyrNoBW6lmtxEFepu19aW21rYzP4hWQnogfKacP7ziaNrgjMsTRBMIt45gb1ekuzVW-SKcNOU0gm8GYZx11Mox1VhucU51CSak_-ZwPNWAq9uLiWlE-DT37UiOYwQlPj5dmXx0vnW1sGiO6q5efmfy3sF90TTHEQwPt2D3c16G17jEW1TjODO_k8-anbiL80VOcA |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NIQESmvgm2xhBQrygrIk_UvdxqzZ1sA4JOtQ3y3Hs0WlKq6Z94L_nLl_TYAyJ19iXxJfzfeTOvwN4P7Aujk3qIumkiEQmfWTQsEXSOMcyjxY6pvPO47N0dC4-TeV0A4btWRgqq2x0f63TK23dXOk13OwtZrPeNxROSfnThBGon1D34D56AzGJ9sn0sFPHqaq6e9DsiKY3J2fqIq9LYwnHMGH7BOXJ2d-s0-OFKZFnvm52cZs3-hvUaGWejp_AVuNXhgf1qz-FDVc8gwfjJnP-HL5MqORi6TA8D4-KH_Sty_AgJ6hwHI-ogwfyIhwSoIFZ_gy_m3Kez66qHHz4tS6kRYpZEVa__csXcH58NBmOoqaZQmSlVKsol2pgRar6LHfWSWu5MYnPFXNJlnNpFdolR96f9Mb63MR9J_O-9xjOKMtFxl_CZjEv3GsImU0zzqz3MeUIs0wNjDGCC596lqPJDyBpmahtgzRODS-udFtSdqmJ8ZoYjyGIRsYH8LGjWdQ4G3fO5u230e0JUtR5Gs3AnVT926hc2WzbUie6ZDrWf4hWALKjvCGd_3zi3g3B6ZbGCCcR7xzAbitJ-votUkHAaULIAN51w7jtKZdjCjdf4xzqEp1QABrAq1oCr2_OOdUT4NM_1CLZjRCW-MV6ofHSxVqXTmM8KhO1_Z_LewsPR5PxqT49Ofu8A49Y1SmERclgFzZXy7V7g_7aKtur9uMvMNw75Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ticagrelor+Enhances+Adenosine-Induced+Coronary+Vasodilatory+Responses+in+Humans&rft.jtitle=Journal+of+the+American+College+of+Cardiology&rft.au=Wittfeldt%2C+Ann&rft.au=Emanuelsson%2C+H%C3%A5kan&rft.au=Brandrup-Wognsen%2C+Gunnar&rft.au=van+Giezen%2C+JJJ&rft.date=2013-02-19&rft.pub=Elsevier+Limited&rft.issn=0735-1097&rft.eissn=1558-3597&rft.volume=61&rft.issue=7&rft.spage=723&rft_id=info:doi/10.1016%2Fj.jacc.2012.11.032&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=3556862441 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F07351097%2FS0735109713X00026%2Fcov150h.gif |